Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients
Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus…
Pfizer Reports Positive Phase 2 Topline Results for Atirmociclib, a Next-Generation CDK4 Inhibitor, in Second-Line Metastatic Breast Cancer
Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1…
Allergan Aesthetics Introduces Skin Quality Index to Transform Skin Health Communication
Allergan Aesthetics Introduces New Skin Quality Index to Transform How Skin Health Is Measured and Communicated Allergan Aesthetics, an AbbVie company, today announced the launch of the Skin Quality Index…
ICON plc Announces Timing Update for Q4 and Full-Year 2025 Earnings and Accounting Investigation
ICON plc announces revised timeline for Q4 and full-year 2025 earnings as investigation into accounting practices continues. ICON plc, today announced that it intends to release its fourth quarter and full…
GSK’s Arexvy RSV Vaccine Gains U.S. Approval for At-Risk Adults Aged 18–49
FDA Expands Approval of GSK’s RSV Vaccine Arexvy to Include At-Risk Adults Aged 18–49 GSK plc today announced that the US Food and Drug Administration (FDA) has expanded the approved…
Novartis’ Cosentyx® Gains FDA Approval for Patients 12 and Older With Moderate-to-Severe Hidradenitis Suppurativa
Novartis’s Cosentyx gains U.S. Food and Drug Administration approval for patients aged 12+ with moderate-to-severe Hidradenitis Suppurativa. Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval…
Johnson & Johnson Reports Encouraging First-in-Human Results for Erda-iDRS (TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Johnson & Johnson Reports Encouraging First-in-Human Data for Erda-iDRS (formerly TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating…
WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership
WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing…
Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Boosting Scale from Development to Commercialization
Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Enhancing Economies of Scale from Development to Manufacturing and Direct Commercialization Celltrion announced today that it will immediately incorporate newly announced…
Johnson & Johnson Secures FDA Approval for TECNIS PureSee Intraocular Lens to Improve Cataract Vision in the U.S.
Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug…
Eli Lilly and Company Issues Safety Warning on Tirzepatide Compounded with Vitamin B12
Eli Lilly and Company Issues Open Letter Warning About Potential Patient Safety Risks of Tirzepatide Compounded with Vitamin B12 Lilly is issuing a public warning about potential safety risks associated…
Curatis, Neupharma Partner to Develop and Commercialize Corticorelin for Brain Edema in Japan
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a…